Oncolyze
Biotech company aiming to treat cancer by exploding cancer cells
Overview
Raised: $0
Total Commitments ($USD)
SeedInvest
08/03/2022
Not Provided
$997
Equity - Preferred
Seed
RegA+
$3.21
$30,000,000
Rolling Commitments ($USD)
02/10/2023
$0
2011
Healthcare & Pharmaceuticals
Biotech
B2B
Medium
High
Balance Sheet
|
Cash and Cash Equivalents |
$179,244 |
| Total Assets |
$272,780 |
|
Accounts Payable & Accrued Liabilities |
$300,706 |
|
Long Term Debt |
$0 |
|
Total Liabilities |
$1,825,924 |
|
Total Stockholders' Equity |
$-1,553,144 |
| Total Liabilities and Equity |
$272,780 |
Statement of Comprehensive Income Information
|
Costs & Expenses Applicable to Rev |
$737,574 |
| Net Income |
$-740,574 |
|
Earnings Per Share - Basic |
$-585.43 |
|
Earnings Per Share - Diluted |
$-585.43 |
Raise History
| Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|---|
| Oncolyze | 02/07/2024 | StartEngine | $29,990,000 | $766,168 | Equity - Preferred | Funded | RegA+ |
| Oncolyze | 02/09/2023 | SeedInvest | $30,000,000 | $0 | Equity - Preferred | Not Funded | RegA+ |
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.
Valuation History
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Employee History
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
